SEARCH

SEARCH BY CITATION

References

  • 1
    Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289293
  • 2
    Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992; 19: 429433
  • 3
    Alexandroff A, Jackson A, O'Donnell M, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 16891694
  • 4
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171 (6 Pt 1): 21862190
  • 5
    Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. Issues Relating to the Use of BCG in Immunization Programs. Geneva: WHO, 1999
  • 6
    Morales A, Eidinger D, Bruce AW. Intracavity bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180183
  • 7
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 12161223
  • 8
    Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247256
  • 9
    Hinotsu S, Akaza H, Naito S et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011; 108: 187195
  • 10
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 16361642
  • 11
    Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumour free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994; 152: 367373
  • 12
    Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410429
  • 13
    Kumar V , Abbas A , Fausto N eds. Robbins and Cotran Pathologic Basis of Disease, 8th edn. 7074. Philadelphia: Elsevier Saunders, 2010
  • 14
    Zlotta AR, van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37: 470477
  • 15
    Fernandez-Gomez J, Solsona E, Unda M et al.; Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 9921001
  • 16
    Palou J, Sylvester RJ, Faba OR et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012; 62: 118125
  • 17
    Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 2011; 107: 4652
  • 18
    Babjuk M, Oosterlinck W, Sylvester R et al.; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 9971008
  • 19
    Kelley DR, Haaff EO, Becich M et al. Prognostic value of the purified derivate skin test and grniloma formation in patients treated with intravesical Bacillus Calmette Guerin. J Urol 1986; 135: 268271
  • 20
    Herr HW, Pinsky CM, Whitmores WF et al. Experience with intravesical Bacillus calmette Guerin therapy of superficial bladder tumours. Urology 1985; 25: 119123
  • 21
    Schellhammer PF, Ladaga LE, Fillion MB. Bacillus Calmette Guerin for superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 261264
  • 22
    Bassi P, Milani C, Meneghini A et al. Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 1992; 40: 175179
  • 23
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratcliff TL. Prognostic factors in patients treated with intravesical Bacillus Calmette Guerin for superficial bladder cancer. J Urol 1988; 139: 941944
  • 24
    Pieras-Ayala E, Palou-Redorta J, Tomero-Ruiz JI, Montlleó-González M, Salvador-Bayarri J, Vicente-Rodríguez J. Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol 2001; 33: 469472